Showing 4351-4360 of 5957 results for "".
- Neurotech Pharmaceuticals Appoints Scott Hunter as Chief Commercial Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-scott-hunter-as-chief-commercial-officer/2481341/Neurotech Pharmaceuticals announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eye care experience across both rare disease and specialty markets. “Scott’s appointment as the company&rsquo
- Acelyrin Acquires ValenzaBio, Maker of Treatment Candidate for Thyroid Eye Diseasehttps://modernod.com/news/acelyrin-acquires-valenzabio-maker-of-treatment-candidate-for-thyroid-eye-disease/2481339/Acelyrin announced the acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. Financial terms of the deal were not disclosed. The acquisition of ValenzaBi
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.
- Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmologyhttps://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-pivotal-phase-3-data-on-nov03-perfluorohexyloctane-in-ophthalmology/2481330/Bausch + Lomb and Novaliq announced that Ophthalmology has published results from the pivotal phase 3 trial GOBI, which is one of two pivotal phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) as
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Bausch + Lomb and Glaucoma Research Foundation Announce Launch of "Screen, Protect, Cure" Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-announce-launch-of-screen-protect-cure-campaign/2481316/Bausch + Lomb and Glaucoma Research Foundation (GRF) announced the US launch of "Screen, Protect, Cure," a campaign designed to provide educational resources and raise awareness of glaucoma during Glaucoma Awareness Month. “We are proud to collaborate with Glau